A5104270902- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer-related molecular mechanisms research
- Neuroendocrine Tumor Research Advances
- Radiation Therapy and Dosimetry
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Inhalation and Respiratory Drug Delivery
- Medical Imaging Techniques and Applications
- Cancer, Stress, Anesthesia, and Immune Response
University of Wisconsin–Madison
2024
Radiation therapy (RT) activates multiple immunologic effects in the tumor microenvironment (TME), with diverse dose-response relationships observed. We hypothesized that, contrast homogeneous RT, a heterogeneous RT dose would simultaneously optimize activation of immunogenic single TME, resulting more effective antitumor immune response. Using high-dose-rate brachytherapy, we treated mice bearing syngeneic tumors fraction at ranging from 2 to 30 gray. When combined dual checkpoint...
Abstract Radiopharmaceutical therapies (RPT) activate a type I interferon (IFN1) response in tumor cells. We hypothesized that the timing and amplitude of this varies by isotope. compared equal doses delivered 90 Y, 177 Lu, 225 Ac vitro as unbound radionuclides vivo when chelated to NM600, tumor-selective alkylphosphocholine. Response murine MOC2 head neck carcinoma B78 melanoma was evaluated qPCR flow cytometry. Therapeutic Ac-NM600+anti-CTLA4+anti-PD-L1 immune checkpoint inhibition (ICI)...
Radiopharmaceutical therapy (RPT) enhances tumor response to immune checkpoint inhibitors (ICI) in preclinical models, but the effects of different radioisotopes have not been thoroughly compared. To evaluate mechanisms RPT+ICI, we used NM600, an alkylphosphocholine selectively taken up by most tumors. Effects 90Y-, 177Lu-, and 225Ac-NM600 + ICIs were compared syngeneic murine B78 melanoma (poorly immunogenic) MC38 colorectal cancer (immunogenic). 90Y-/177Lu-/or delivering 2 Gy mean dose...